Spots Global Cancer Trial Database for Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
Official Title: Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer
Study ID: NCT01100658
Conditions
Study Description
Brief Summary: While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.
Detailed Description:
Keywords
Eligibility
Minimum Age: 8 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Locations
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Contact Details
Name: Alicia Kunin-Batson, Ph.D.
Affiliation: Masonic Cancer Center, University of Minnesota
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
